Background-Blacks have a higher prevalence of left ventricular hypertrophy than whites. Several population-based studies have reported an inverse association between adiponectin and left ventricular mass (LVM); however, the relationship between adiponectin levels and LVM has yet to be defined in blacks. The Jackson Heart Study cohort provides an opportunity to test the hypothesis that the inverse association between adiponectin and LVM may be modified by risk factors common among blacks.
O bese individuals, particularly those with visceral fat accumulation, have reduced plasma levels of adiponectin. 1, 2 The associations of adiponectin with cardiac risk factors, such as hypertension, type 2 diabetes mellitus, and obesity, have been described previously. 3, 4 In mice, adiponectin inhibits hypertrophic signaling in the myocardium. 5 Several studies have reported an inverse association between adiponectin and left ventricular mass (LVM). 6 -12 There are, however, very few large community-based studies with adequate adjustment for potential confounders to elucidate this apparent inverse relationship between adiponectin and LVM in greater detail. [13] [14] [15] Although blacks have a higher prevalence of obesity and left ventricular hypertrophy, the relationship between adiponectin and LVM in this population has yet to be explored.
Clinical Perspective on p 753
The availability of serum adiponectin measurements for more than 4000 black participants in the Jackson Heart Study (JHS) allowed us to quantify the association between serum adiponectin and echocardiography-measured LVM in blacks enrolled in the JHS, a large community-based cohort. We queried whether an inverse association between adiponectin and LVM is present and whether this association is modified by selected covariates such as hypertension, obesity, and insulin resistance that are known to be particularly prevalent among blacks and are associated with LVM.
Methods

Study Population
JHS is a single-site, prospective cohort study of the risk factors and causes of cardiovascular disease in adult blacks. A probability sample of 5301 blacks, 21 to 84 years of age, residing in the 3 counties surrounding Jackson, MS, were recruited and examined at baseline (2000 -2004) by trained and certified technicians according to standardized protocols. Clinic visits and interviews occurred approximately every 3 years. Annual follow-up interviews and cohort surveillance are ongoing. Details of the study design have been published elsewhere. 16, 17 After exclusion of individuals with prevalent coronary heart disease (nϭ375), undetectable adiponectin levels (nϭ93), unreliable ultrasound measurements (nϭ879), and mitral or aortic regurgitation (nϭ1305), the final study sample included 2649 participants. Written consent was obtained from each participant at the inception of the study, and the study protocol was approved by the institutional review boards of the Morehouse School of Medicine and the University of Mississippi Medical Center.
For all participants, the clinic visit included physical examination, anthropometry, survey of medical history and of cardiovascular risk factors, and collection of blood and urine for biological variables. We calculated body mass index (BMI; kg/m 2 ) as weight in kilograms divided by height in meters squared. Obesity was defined as BMI Ն30 kg/m 2 and abdominal obesity as a waist circumference Ն88 cm in women and Ն102 cm in men. Hypertension was defined as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or use of antihypertensive therapy. Diabetes was defined as fasting plasma glucose Ն126 mg/dL or use of insulin or oral hypoglycemic medications. Smoking status was defined as current smoking versus former and never smoking (collapsed). Alcohol drinking was defined as regular drinking in the past 12 months (yes versus no). A physical activity score was composed with a Baecke-derived questionnaire and used as a continuous variable.
Participants were further subjected to a standardized 2-dimensional echocardiographic examination. LVM was calculated with the American Society of Echocardiography corrected formula reported by Devereux et al. 18 LVM was indexed (LVMI) to height raised to the 2.7th power (LVMIϭLVM/height 2.7 ) to normalize heart size to body size.
Lipid variables, fasting plasma glucose, and fasting insulin were measured by standard laboratory techniques. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as [insulin (microunits per milliliter)ϫfasting blood glucose (millimoles per liter)]/22.5. Insulin resistance status was defined as an HOMA-IR in the highest quartile of its distribution. 19, 20 
Adiponectin Measurement
Venous blood samples were withdrawn from each subject at baseline examination after more than 8 hours of fasting, as described elsewhere. 16 Serum concentration of adiponectin was measured as total adiponectin at the JHS central laboratory in Minneapolis, MN, by an ELISA system (R&D Systems; Minneapolis, MN) using baseline serum specimens stored at Ϫ80°C until they were assayed. The interassay coefficient of variation was 8.8%. No biological degradation has been described with stored specimens, which indicates a high validity for our measurements. 21
Statistical Analyses
Because the distributions of adiponectin and HOMA-IR were skewed, log-transformed values were used for the analyses to approximately normalize the distribution. The cross-sectional asso-ciation between adiponectin and LVMI was assessed with Spearman correlation coefficients and multiple linear regression. Using full models, we assessed the individual effect measure modification for a series of covariates (age, sex, hypertension, obesity and abdominal obesity, diabetes, and insulin resistance status) known to be associated with both adiponectin 22 and LVM. 23, 24 Models that included hypertension and insulin resistance were used to also test the 3-way interaction between adiponectin, hypertension and insulin resistance, on LVMI. These models were constructed by including within the models that adjusted for age and sex the 3-variable interaction term "adiponectin by hypertension by insulin resistance," as well as the 2-variable interaction terms "adiponectin by hypertension" and "adiponectin by insulin resistance." The multivariable regression full models were adjusted for age, sex, BMI, alcohol drinking, triglycerides, high-density lipoprotein cholesterol, hypertension status, and HOMA-IR. We also modeled continuous LVM as a nonlinear predictor of adiponectin concentrations using a generalized additive model. In the generalized additive model, we used a penalized spline smoothing function to fit a curve that describes the relationship between adiponectin and LVM without assuming a linear relationship. For all the analyses, the nominal probability value was set at 0.05 for the main and the interactive effects. Analyses were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC).
Additional Analyses
Because hypertension medication directly influences blood pressure values, a direct determinant of LVM, we also ran the same analyses after excluding 1118 subjects who had been undergoing medical treatment for hypertension. We also assessed the effects of the use of medications that inhibit the renin-angiotensin-aldosterone system (such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) and of statins, all of which are reported to increase adiponectin levels.
Results
The overall characteristics of the JHS study sample (mean age ϮSD 51Ϯ12 years; 63% women) are as follows: BMI had a mean (SD) of 31.3 (6.9) kg/m 2 . Obesity had a prevalence of 51%, and the prevalence of abdominal obesity was 60.5%. Systolic blood pressure ranged from 73 to 210 mm Hg, and the mean was 124 mm Hg. Hypertension was present in 54% of participants. The prevalence of diabetes was 15.7%. Serum adiponectin level ranged from 0.4 to 41.4 g/mL, and the mean was 5.1 g/mL. LVM ranged from 66.4 to 379.9 g, and the mean was 144.0 g. The characteristics of the participants across adiponectin quartiles are presented in Table 1 . Age, sex, BMI, alcohol drinking, hypertension status, high-density lipoprotein cholesterol, triglycerides, and HOMA-IR emerged as the main variables that had a statistically significant variance across quartiles.
In accordance with previous observations, serum adiponectin levels had a positive and statistically significant correlation with high-density lipoprotein cholesterol (Spearman rϭ0.43) and a negative correlation with HOMA-IR (rϭϪ0.36), triglycerides (rϭϪ0.29), waist circumference (rϭϪ0.24), and BMI (rϭ Ϫ0.15; all PϽ0.0001). There was no statistically significant correlation between adiponectin and systolic blood pressure (rϭ0.02; Pϭ0.21). In the overall sample, we observed a statistically significant negative correlation between adiponectin levels and LVM (rϭϪ0.19; Pϭ0.0001) and between adiponectin and LVMI (rϭϪ0.04; Pϭ0.047).
Several effect modifiers emerged as statistically significant: hypertension (Pϭ0.03), insulin resistance (Pϭ0.01), and hypertension in conjunction with insulin resistance (Pϭ0.04). Sex and obesity did not appear to affect the adiponectin-LVMI relationship as effect modifiers. On the basis of the finding that hypertension and insulin resistance were significant effect modifiers, the subsequent analyses were performed based on substratification by these variables. Among the normotensive participants (nϭ1206), the significant inverse association between adiponectin and LVMI present in the crude model appeared to be mediated by measures of obesity such as BMI and by insulin resistance ( Table 2 ). It is notable that there was no significant association between adiponectin and LVMI among participants with hypertension and that this association became statistically significant when adjusted for BMI or insulin resistance ( Table 2 ). The variance explained in the fully adjusted models was 22%.
To further define the effect of the interaction of hypertension and insulin resistance on the adiponectin-LVMI relationship, the entire sample was substratified by both variables, as shown in Table 3 . The inverse association between adiponectin and LVM that was found among participants without hypertension or insulin resistance (mϭ998) was explained by BMI (Table 3 ). Among those with hypertension and insulin resistance (nϭ331), the association was a statistically significant direct association that persisted after adjustment for age, sex, BMI, high-density lipoprotein cholesterol, triglycerides, and alcohol drinking (␤ϭ1.55, Pϭ0.04; Table 3 ). The equivalent raw values of the log-transformed ␤-coefficients (ob-tained by exponentiation of the initial values) were on the order of 5 to 13 and thus of a very large magnitude. Table I in the online-only Data Supplement presents the ␤-coefficients for LVMI across adiponectin quartiles using raw values of adiponectin levels to ensure easier interpretation of the regression model results. This table confirms a nonlinear complex trend in the association between adiponectin and LVMI. Using spline regression with multivariable adjustment, we observed a significant curvilinear bidirectional relationship between adiponectin and LVMI among normotensive participants (Pϭ0.001; nϭ1206; Figure 1 ). The spline regression analysis among hypertensive subjects with insulin resistance exhibited the same curvilinear adiponectin-LVMI relationship (Pϭ0.04; nϭ331; Figure 2 ). Among participants with hypertension, a direct relationship between adiponectin and LVMI emerged, although it was not statistically significant (online-only Data Supplement Figure I) . Curvilinear bidirectional adiponectin-LVMI relationships also emerged among those without hypertension and without insulin resistance (nϭ998), among those without hypertension and with insulin resistance (nϭ208), and among those with hypertension and without insulin resistance (nϭ1087), relationships that reached statistical significance in the second-mentioned group (online-only Data Supplement Figures II, III, and IV).
Similar results were obtained among participants without medication for hypertension (nϭ1531). Specifically, the ␤-coefficients changed their sign from ␤ϭϪ0.78 (Pϭ0.02) among participants without hypertension and without insulin resistance (age-and sex-adjusted model) to ␤ϭ3.32 (Pϭ0.008) among those with both hypertension and insulin resistance (fully adjusted model). Moreover, in the assessment of the potential confounding effects of the use of medication that inhibits the renin-angiotensin-aldosterone system and of statins, we did not find among hypertensive subjects any statistically significant effect on the adiponectin-LVMI relationship (online-only Data Supplement). Similarly, we did not observe significant differences in the mean level of adiponectin among hypertensive subjects compared with normotensive subjects either with or without insulin resistance (data not shown). The association between adiponectin and LVMI according to hypertension, diabetes, and abdominal obesity stratified by age (an effect modifier when dichotomized with the median age of 50 years used as the cutpoint) and sex is presented in online-only Data Supplement Tables II and III. Among participants without hypertension, the inverse association became nonsignificant after adjustment for age, BMI, or insulin resistance in both men and women but was maintained among younger participants.
Discussion
Principal Findings
In accordance with previous studies, we observed a modest negative correlation between adiponectin and LVMI in the overall JHS community-based sample of blacks. Hypertension and insulin resistance emerged as the major effect modifiers of the adiponectin-LVMI relationship. A statistically significant inverse association was evident among normotensive subjects in the crude model, but this association was attenuated in multivariate models by the effects of adiposity and insulin resistance. The observation of a statistically significant direct association between adiponectin and LVMI among those with both hypertension and insulin resistance, which was not hypothesized a priori, was intriguing.
Results in the Context of Previous Studies
The prevalence of cardiovascular disease and diabetes is greater in blacks than in whites. 25 Several studies, such as CARDIA (Coronary Artery Risk Development in Young Adults), 26, 27 HyperGEN, 28 and the Dallas Heart Study, 29 have shown that blacks have an increased LVM and an increased prevalence of concentric left ventricular hypertrophy compared with whites. In epidemiological investigations, cardiovascular risk factors such as diabetes, hypertension, smoking, and obesity have been shown to be associated with increased LVMI. 30 -32 The role of adiponectin in relation to cardiac mass and function has attracted some recent attention. Studies performed in small study samples have reported an inverse association between adiponectin and LVM, but the study participants for these investigations were mainly from hospital-based or convenience samples, or the studies involved patients with preexisting disease, such as type 2 diabetes mellitus, hypertension, or obesity. 6 -12 Only 3 large community-based studies with adequate adjustment for potential confounders are available. [13] [14] [15] A significant inverse association between adiponectin and ECG-measured left ventricular hypertrophy in apparently healthy individuals with normal and high blood pressure was observed in 2839 Japanese male workers who were not taking medications for hypertension. 13 In 2 community-based samples of Swedish elderly, adiponectin concentrations were inversely associated with ejection fraction in men but not with LVMI after adjustment for potential confounders. 14 In 2615 participants from the Framingham Offspring Study, adiponectin concentrations were inversely related to LVM but not to cardiac structure and function markers in linear regression models that adjusted for clinical correlates. 15 To the best of our knowledge, the present study is among the first to examine the adiponectin-LVM relationship in blacks, a population group at high risk for left ventricular hypertrophy.
Potential Mechanisms
A growing body of evidence suggests that a decrease in adiponectin plasma levels plays an important part in the pathogenesis of many comorbid conditions, such as insulin resistance, diabetes, and atherosclerosis. 3, 33, 34 Experimental studies have demonstrated that decreased plasma adiponectin levels can predispose to left ventricular hypertrophy. Similarly, increased adiponectin expression can attenuate left ventricular hypertrophy induced by pathological stimuli. 5 Adiponectin may directly inhibit hypertrophic signaling in the myocardium by activating adenosine monophosphate-activated kinase, which activates eukaryotic elongation factor-2 kinase and the inhibitor of cardiac myocyte protein synthesis. 35 Adiponectin protects the ischemic heart from injury through the activation of independent pathways that involve both adenosine monophosphate-activated kinase-mediated antiapoptotic actions and cyclooxygenase-2mediated antiinflammatory actions. 22 These mechanistic studies of the antihypertrophic properties of adiponectin are consistent with the finding of an inverse association between adiponectin and LVMI.
Although we observed an inverse adiponectin-LVMI relationship among normotensive blacks, we are intrigued by the "paradoxical" observation of a direct adiponectin-LVMI relationship among hypertensive subjects with insulin resistance. The mechanistic basis of this finding remains to be further defined. Although the primary determinants of adiponectin levels are related to adipose tissue, adiponectin is also expressed in both cardiac and skeletal muscle under certain circumstances. Increased levels of adiponectin have been described in patients with both systolic and diastolic forms of heart failure. 36, 37 Moreover, increased adiponectin expression has been noted in the context of a high-salt diet and increased activation of the renin-angiotensin-aldosterone system. 38 -42 We speculate that the positive adiponectin-LVM relationship reflects a common set of determinants: a highsalt diet, activation of the renin-angiotensin-aldosterone system, and hypertension. These findings suggest that the prognostic value of adiponectin levels may be contextual and that these levels depend on factors involved in blood pressure regulation in addition to metabolic factors such as adiposity.
In addition, recent studies have documented that adiponectin exerts an antiapoptotic effect that is mediated by elevated sphingosine-1-phosphate levels. 43 These findings suggest that adiponectin could contribute to the expansion of the total number of cells in the heart and increase LVM in the cardiotoxic context of hypertension and insulin resistance. Similarly, there is evidence that certain antihypertrophic pathways induced by adiponectin can become downregulated in certain contexts characterized by a state of "adiponectin resistance." 44, 45 Taken together, these studies are consistent with the possibility that the nature of the adiponectin-LVM relationship may be context specific. Future studies are needed to define the implications of both direct and inverse associations between adiponectin and LVM.
Strengths and Limitations
Strengths of the present study include that it is the largest community-based cohort of exclusively blacks with a wide range of biological, behavioral, and demographic attributes and that the study used strict quality control methods. Some limitations should be acknowledged. Because this is a crosssectional study, causality cannot be elucidated, nor can it be determined whether LVM is related to the longitudinal tracking of adiponectin concentrations. Second, measures of different multimeric forms of serum adiponectin were not available for the present study. This could be of importance, because some studies suggest a difference in biological activity between different isoforms of adiponectin with regard to metabolic abnormalities 46 and ventricular mass. 10
Conclusions
The major finding of the present study was an inverse relationship between serum adiponectin and LVMI in normotensive and non-insulin-resistant participants. This association became nonsignificant after multivariable adjustment that included obesity measures. On the other hand, serum adiponectin was directly associated with LVMI in participants with hypertension and insulin resistance. This suggests that plasma adiponectin levels may have a different prognostic value related to LVM depending on the metabolic context and the underlying risk factors.
